Clinical trial · Observational
The Bacterial Composition of the Stomach in Reflux Disease
Identification of Bacteria Responsible for the the Development of Oesophago-gastric Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Gastric and oesophageal (OG) cancer associated with poor long term outcome as overall less than 25% of patients survive for more than 5 years due to late recognition of the disease. Growing evidence suggests an important role for bacteria in OG cancer and gastro esophageal reflux disease (GORD) development. About 1 in 10 people suffer from GORD and this one of the most common conditions leading to gastric and oesophageal cancer. In GORD surgical therapy is the most successful preventing cancer but around 85% of patient experience complications afterwards. Acid suppressing medications are reducing the risk of oesophageal cancer but equally increasing the risk of gastric cancer. They also shorten patients' life expectancy and often fail to provide relief. Analysis of stool samples of patients with GORD demonstrated different gut bacterial compositions to normal and rather resembled the one found in cancer. There is a clear need to improve the outcome of OG cancer. This could be achieved by identifying bacteria responsible for cancer development in gastric tissue, gastric content and saliva and potentially eliminate them hence avoid the development of cancer.
Conditions
Conditions (8)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Barrett Esophagus | — | UNRESOLVED | — |
| Esophagitis | — | UNRESOLVED | — |
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Gastro Esophageal Reflux | — | UNRESOLVED | — |
| GORD | — | UNRESOLVED | — |
| Oesophageal Cancer | — | UNRESOLVED | — |
| Oesophageal Carcinoma | — | UNRESOLVED | — |
| Oesophageal Reflux | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No intervention but patients are undergoing an upper GI endoscopy and biopsies for clinical purposes | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Patients with non erosive reflux
- description
- Patients with symptoms of reflux but no evidence of oesophagitis or Barretts oesophagus on endoscopy.
- interventionNames
- Diagnostic Test: No intervention but patients are undergoing an upper GI endoscopy and biopsies for clinical purposes
- label
- Patients with erosive reflux
- description
- Patients with symptoms of reflux with evidence of oesophagitis or Barretts oesophagus on endoscopy.
- interventionNames
- Diagnostic Test: No intervention but patients are undergoing an upper GI endoscopy and biopsies for clinical purposes
- label
- Patients with no reflux
- description
- Patients with healthy oesophago-gastric mucosa and no symptoms of reflux.
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who deemed necessary for an upper gastro intestinal endoscopy for clinical reasons and consent for additional gastric mucosal biopsies for study purposes Exclusion Criteria: * Patients who have upper GI malignancy
References
Publications (0)
Data not yet available